Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:03 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 835 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Intramuscular vaccine Clear all

Conditions: HPV
Interventions: Gardasil-9, Lidocaine injection, Lorazepam; Biological · Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Decatur, Georgia

Conditions: Glabellar Frown Lines
Interventions: Botulinum Toxins, Type A, Placebos; Biological
Lead sponsor: Revance Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 303 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 15
States / cities: Birmingham, Alabama • Beverly Hills, California • Newport Beach, California + 11 more

Conditions: Influenza
Interventions: Fluzone®: Influenza Virus Vaccine; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Influenza
Interventions: Phosphate Buffered Saline (PBS) diluent, MF59 Adjuvant, H5N1 Antigen; Other · Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 270 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 5
States / cities: Atlanta, Georgia • Decatur, Georgia • Iowa City, Iowa + 2 more

Conditions: Pneumococcal Infections
Interventions: V114, Prevnar 13™, PNEUMOVAX™23; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 3 Years and older
Enrollment: 277 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 13
States / cities: Palo Alto, California • Aurora, Colorado • Gainesville, Florida + 10 more

Conditions: Diphtheria, Tetanus, Haemophilus Infection, Pertussis, Polio
Interventions: Pentacel™: HCPDT-IPV//PRP-T Vaccine and Prevnar®; Biological
Lead sponsor: Sanofi; Industry
Eligibility: 42 Days to 89 Days
Enrollment: 1,167 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2006
U.S. locations: 23
States / cities: Montgomery, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 19 more

Conditions: Cytomegalovirus
Interventions: mRNA-1647, Placebo; Biological · Other
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 9 Years to 25 Years
Enrollment: 873 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 44
States / cities: La Mesa, California • Sacramento, California • Fort Collins, Colorado + 38 more

Conditions: Ricin Poisoning
Interventions: RVEc; Biological
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 50 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Fort Deterick, Maryland

Conditions: Influenza A Subtype H7N7 Infection
Interventions: Monovalent Influenza Subvirion Vaccine, H7N7; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Pneumococcal Conjugate Vaccine
Interventions: 13-valent Pneumoccocal Conjugate Vaccine; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 5
States / cities: Birmingham, Alabama • Louisville, Kentucky • The Bronx, New York + 1 more

Conditions: Influenza
Interventions: Influenza A/H3N2 variant Vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 211 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 4
States / cities: Decatur, Georgia • Iowa City, Iowa • Houston, Texas + 1 more

Conditions: Dermatitis Atopic
Interventions: Amlitelimab, Placebo, Tdap vaccine, PPS vaccine; Drug · Biological
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 47
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Anaheim, California + 40 more

Conditions: Hepatitis, Safety and Tolerability
Interventions: HEPLISAV-B; Biological
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Influenza
Interventions: Influenza Vaccination; Biological
Lead sponsor: Protein Sciences Corporation; Industry
Eligibility: 65 Years and older
Enrollment: 870 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 7
States / cities: Baltimore, Maryland • Rochester, Minnesota • Shrewsbury, New Jersey + 3 more

Conditions: HIV Infections, H1N1 Influenza Virus
Interventions: Influenza A (H1N1) 2009 monovalent vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 4 Years to 25 Years
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 35
States / cities: Birmingham, Alabama • Alhambra, California • La Jolla, California + 25 more

Conditions: Hookworm Infection
Interventions: Na-ASP-2/Alhydrogel Hookworm Vaccine, Saline placebo; Biological
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 45 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Influenza, Pandemic
Interventions: BW-1014: 25 µg rH5 in 20% NE - pipette - IN, BW-1014: 50 µg rH5 in 20% NE - pipette - IN, BW-1014: 100 µg rH5 in 20% NE - pipette - IN, rH5 (100 µg) control - pipette - IN, Saline (Placebo) - pipette - IN, H5N1 IIV - IM; Biological
Lead sponsor: BlueWillow Biologics; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Influenza
Interventions: Fluarix, Fluzone; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 6 Months to 35 Months
Enrollment: 3,317 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 62
States / cities: Birmingham, Alabama • Dothan, Alabama • Benton, Arkansas + 58 more

Conditions: SARS-CoV-2
Interventions: mRNA-1283, mRNA-1283.211, mRNA-1273, mRNA-1283.529; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 540 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 17
States / cities: Phoenix, Arizona • Hollywood, Florida • Sunrise, Florida + 13 more

Conditions: HIV Infections
Interventions: MN rgp120/HIV-1 and GNE8 rgp120/HIV-1, ALVAC-HIV MN120TMG (vCP205), ALVAC-RG Rabies Glycoprotein (vCP65); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2000
U.S. locations: 6
States / cities: Birmingham, Alabama • Baltimore, Maryland • St Louis, Missouri + 3 more

Conditions: Hepatitis B, Chronic
Interventions: HepTcell, Placebo; Biological · Drug
Lead sponsor: Altimmune, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 5
States / cities: Garden Grove, California • Redwood City, California • San Jose, California + 2 more

Conditions: Influenza
Interventions: Inactivated Influenza H1N1 vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 64 Years
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 6
States / cities: Iowa City, Iowa • Baltimore, Maryland • St Louis, Missouri + 3 more

Conditions: Pneumococcal Disease
Interventions: PG4, 20-valent pneumococcal conjugate vaccine (20vPnC); Biological
Lead sponsor: Pfizer; Industry
Eligibility: 15 Months to 17 Years
Enrollment: 1,200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 62
States / cities: Birmingham, Alabama • Guntersville, Alabama • Fair Oaks, California + 37 more

Conditions: Breast Cancer
Interventions: PVX-410, Durvalumab, Hiltonol; Biological · Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 5
States / cities: Tampa, Florida • Boston, Massachusetts • New York, New York

Search by objective public record fields.

HPV Vaccine Reduced Dose

Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines

Safety and Immunogenicity of the 2005-2006 Fluzone® Vaccine

H5N1 Mix and Match With MF59

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Allogeneic Hematopoietic Stem Cell Transplant Recipients (V114-022/PNEU-STEM)

Study of the Effect of Pneumococcal Conjugate Vaccine (PCV) on Immunogenicity of Pentacel™

A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age

IM Recombinant Ricin Toxin Vaccine (RVEc) - 3-Dose Primary Series With Boost

Evaluating the Safety and Immune Response of an H7N7 Vaccine in Healthy Adults

Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Children With Sickle Cell Disease

Safety and Immunogenicity of a Monovalent Inactivated Influenza H3N2 Variant (H3N2v) Vaccine in Adult and Elderly Populations

A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo

HEPLISAV-B Hepatitis B Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's-Tyrosine Kinase Inhibitor (BTK-I)

Comparison of the Immunogenicity, Safety and Reactogenicity of FluBlok, To a Licensed Vaccine In Elderly Adults

Safety of and Immune Response to an H1N1 Influenza Virus Vaccine in HIV Infected Children and Youth

Study of Na-ASP-2 Human Hookworm Vaccine in Healthy Adults Without Evidence of Hookworm Infection

A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Pandemic Flu Vaccine in Healthy Adults

Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine Versus a Licensed Comparator in Children

A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Vaccine Boosters

A Randomized Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 Delivered by Alternate Mucosal Routes in HIV-1 Uninfected Adult Volunteers

HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB)

H1N1 Vaccine at Two Dose Levels in HIV Positive Adults

Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccine in Children and Adolescents

Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer